中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 654-658

Management of hepatitis C in children and pregnant women

DOI: 10.12449/JCH240402
  • 1.

    Department of Infectious Diseases，The Second Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710004，China

  • 2.

    Department of Infectious Diseases，The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China

Research funding:

National Natural Science Foundation of China (82170626);

National Natural Science Foundation of China (82270629);

Innovation and Entrepreneurship Training Program of Xi’an Jiaotong University (S202110698159)

More Information
  • Corresponding author: JI Fanpu， jifanpu1979@163.com （ORCID： 0000-0002-1463-8035）; ZENG Qinglei， zengqinglei2009@163.com （ORCID： 0000-0002-2094-4784）
  • Received Date: 2024-03-10
  • Accepted Date: 2024-03-24
  • Published Date: 2024-04-25
    Abstract
  • Hepatitis C virus infection is a global public health issue， and the emergence of direct-acting antiviral agents has brought revolutionary breakthroughs in the treatment of hepatitis C patients. Although direct-acting antiviral agents have a marked therapeutic effect in adult patients， there are still many challenges in the treatment of special populations such as pregnant women， infants， young children， and adolescents. This article reviews the current status of antiviral therapy for these special populations with hepatitis C and the problems that need to be solved， in order to provide reference and guidance for clinical workers.

     

    • FullText(HTML)
  • loading
    • References(33)
  • [1]
    DUGAN E, BLACH S, BIONDI M, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: A modelling study[J]. Lancet Gastroenterol Hepatol, 2021, 6( 3): 169- 184. DOI: 10.1016/s2468-1253(20)30359-9.
    [2]
    ABBASI F, ALMUKHTAR M, FAZLOLLAHPOUR-NAGHIBI A, et al. Hepatitis C infection seroprevalence in pregnant women worldwide: A systematic review and meta-analysis[J]. EClinicalMedicine, 2023, 66: 102327. DOI: 10.1016/j.eclinm.2023.102327.
    [3]
    SALARI N, KAZEMINIA M, HEMATI N, et al. Global prevalence of hepatitis C in general population: A systematic review and meta-analysis[J]. Travel Med Infect Dis, 2022, 46: 102255. DOI: 10.1016/j.tmaid.2022.102255.
    [4]
    KUSHNER T, DJERBOUA M, BIONDI MJ, et al. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission[J]. J Hepatol, 2022, 77( 5): 1256- 1264. DOI: 10.1016/j.jhep.2022.05.016.
    [5]
    REDDICK KLB, JHAVERI R, GANDHI M, et al. Pregnancy outcomes associated with viral hepatitis[J]. J Viral Hepat, 2011, 18( 7): e394- e398. DOI: 10.1111/j.1365-2893.2011.01436.x.
    [6]
    BENOVA L, MOHAMOUD YA, CALVERT C, et al. Vertical transmission of hepatitis C virus: Systematic review and meta-analysis[J]. Clin Infect Dis, 2014, 59( 6): 765- 773. DOI: 10.1093/cid/ciu447.
    [7]
    BHATTACHARYA D, ARONSOHN A, PRICE J, et al. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection[J]. Clin Infect Dis, 2023: ciad319. DOI: 10.1093/cid/ciad319.
    [8]
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol, 2020, 73( 5): 1170- 1218. DOI: 10.1016/j.jhep.2020.08.018.
    [9]
    CHAILLON A, RAND EB, REAU N, et al. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States[J]. Clin Infect Dis, 2019, 69( 11): 1888- 1895. DOI: 10.1093/cid/ciz063.
    [10]
    THOMPSON LA, PLITT SS, DOUCETTE K, et al. Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada[J]. J Hepatol, 2023, 79( 5): 1121- 1128. DOI: 10.1016/j.jhep.2023.05.044.
    [11]
    ZENG QL, YU ZJ, LV J, et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study[J]. J Med Virol, 2022, 94( 9): 4548- 4553. DOI: 10.1002/jmv.27877.
    [12]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
    [13]
    ZENG QL, JI FP. Interpretation of guideline for the prevention and treatment of hepatitis C(2022 version): Antiviral therapy for special populations[J]. J Clin Hepatol, 2023, 39( 7): 1560- 1563. DOI: 10.3969/j.issn.1001-5256.2023.07.008.

    曾庆磊, 纪泛扑.《丙型肝炎防治指南(2022年版)》解读: 特殊人群抗病毒治疗[J]. 临床肝胆病杂志, 2023, 39( 7): 1560- 1563. DOI: 10.3969/j.issn.1001-5256.2023.07.008.
    [14]
    CHAPPELL CA, SCARSI KK, KIRBY BJ, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study[J]. Lancet Microbe, 2020, 1( 5): e200- e208. DOI: 10.1016/S2666-5247(20)30062-8.
    [15]
    YATTOO GN, SHAFI SM, DAR GA, et al. Safety and efficacy of treatment for chronic hepatitis C during pregnancy: A prospective observational study in Srinagar, India[J]. Clin Liver Dis, 2023, 22( 4): 134- 139. DOI: 10.1097/CLD.0000000000000082.
    [16]
    ABDALLAH M, ALBORAIE M, ABDEL-RAZEK W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort[J]. Liver Int, 2021, 41( 7): 1494- 1497. DOI: 10.1111/liv.14913.
    [17]
    YE WH, XU Y. Research progress on vertical transmission mechanism and risk factors of hepatitis C virus from mother to child[J]. Chin J Pediatr, 2018, 56( 6): 477- 479. DOI: 10.3760/cma.j.issn.0578-1310.2018.06.018.

    叶文辉, 徐翼. 丙型肝炎病毒母婴垂直传播机制及危险因素研究进展[J]. 中华儿科杂志, 2018, 56( 6): 477- 479. DOI: 10.3760/cma.j.issn.0578-1310.2018.06.018.
    [18]
    PANAGIOTAKOPOULOS L, SANDUL AL, DHSC, et al. CDC recommendations for hepatitis C testing among perinatally exposed infants and children-United States, 2023[J]. MMWR Recomm Rep, 2023, 72( 4): 1- 21. DOI: 10.15585/mmwr.rr7204a1.
    [19]
    ZHU SS, ZENG QL, DONG Y, et al. Interferon-α plus ribavirin yields 98% sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C[J]. Hepatol Int, 2015, 9( 4): 578- 585. DOI: 10.1007/s12072-015-9671-8.
    [20]
    HE S, WANG XY, HAN QY, et al. Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C[J]. Chin J Hepatol, 2021, 29( 1): 83- 86. DOI: 10.3760/cma.j.cn501113-20190606-00199.

    贺珊, 王小云, 韩群英, 等. 基于索磷布韦的方案在未成年慢性丙型肝炎患者中的应用[J]. 中华肝脏病杂志, 2021, 29( 1): 83- 86. DOI: 10.3760/cma.j.cn501113-20190606-00199.
    [21]
    TUCCI F, CALBI V, BARZAGHI F, et al. Successful treatment with ledipasvir/sofosbuvir in an infant with severe combined immunodeficiency caused by adenosine deaminase deficiency with HCV allowed gene therapy with strimvelis[J]. Hepatology, 2018, 68( 6): 2434- 2437. DOI: 10.1002/hep.30160.
    [22]
    CONTE D, FRAQUELLI M, PRATI D, et al. Prevalence and clinical course of chronic hepatitis C virus(HCV) infection and rate of HCV vertical transmission in a cohort of 15, 250 pregnant women[J]. Hepatology, 2000, 31( 3): 751- 755. DOI: 10.1002/hep.510310328.
    [23]
    SQUIRES JE, BALISTRERI WF. Hepatitis C virus infection in children and adolescents[J]. Hepatol Commun, 2017, 1( 2): 87- 98. DOI: 10.1002/hep4.1028.
    [24]
    World Health Organization. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics[EB/OL].( 2022-06-24). Geneva: World Health Organization, 2022.
    [25]
    ROSENTHAL P, SCHWARZ KB, GONZALEZ-PERALTA RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to<12 years with hepatitis C virus genotype 2 or 3 infection[J]. Hepatology, 2020, 71( 1): 31- 43. DOI: 10.1002/hep.30821.
    [26]
    MURRAY KF, BALISTRERI WF, BANSAL S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11[J]. Hepatology, 2018, 68( 6): 2158- 2166. DOI: 10.1002/hep.30123.
    [27]
    SCHWARZ KB, ROSENTHAL P, MURRAY KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to<6 years old with chronic hepatitis C[J]. Hepatology, 2020, 71( 2): 422- 430. DOI: 10.1002/hep.30830.
    [28]
    EL-KARAKSY H, MOGAHED EA, ABDULLATIF H, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir[J]. J Pediatr Gastroenterol Nutr, 2018, 67( 5): 626- 630. DOI: 10.1097/MPG.0000000000002101.
    [29]
    JONAS MM, SQUIRES RH, RHEE SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA study[J]. Hepatology, 2020, 71( 2): 456- 462. DOI: 10.1002/hep.30840.
    [30]
    SOKAL EM, SCHWARZ KB, ROSENTHAL P, et al. Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection in children and adolescents aged 3 to 17 years old through 24 weeks posttreatment[J]. Hepatology, 2020, 72: 570A.
    [31]
    EL-SAYED MH, EBEID FSE, ZEKRI AR, et al. Ledipasvir-sofosbuvir in adolescents with chronic hepatitis C and hematological malignancies undergoing chemotherapy[J]. J Pediatr Gastroenterol Nutr, 2022, 74( 5): 626- 630. DOI: 10.1097/MPG.0000000000003406.
    [32]
    IMAM U, PARKASH A, DARYANI N, et al. Usefulness of sofosbuvir and daclatasvir combination in the treatment of HCV infection in childhood cancer patients: Experience from A tertiary care hospital[J]. J Pak Med Assoc, 2023, 73( 11): 2183- 2188. DOI: 10.47391/JPMA.8433.
    [33]
    MAKHLOUF NA, ABDELMALEK MO, IBRAHIM ME, et al. Ledipasvir/sofosbuvir in adolescents with chronic hepatitis C genotype 4 with and without hematological disorders: Virological efficacy and impact on liver stiffness[J]. J Pediatric Infect Dis Soc, 2021, 10( 1): 7- 13. DOI: 10.1093/jpids/piaa006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (363) PDF downloads(125) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return